ClinicalTrials.gg
Active, not recruitingNCT01684397Updated Nov 5, 2026

Pazopanib Hydrochloride and Bevacizumab in Treating Patients With Previously Untreated Metastatic Kidney Cancer

A Phase 1/2 interventional study of Bevacizumab and Laboratory Biomarker Analysis in Clear Cell Renal Cell Carcinoma and Stage IV Renal Cell Cancer, sponsored by Roswell Park Cancer Institute. Active, not recruiting at 5 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-05.

Sponsored by Roswell Park Cancer Institute · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 5, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
51
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 44 studies testing bevacizumab in Carcinoma, Renal Cell — 1 open to participants now, 3 under way, none of them phase 3. Bevacizumab · Carcinoma, Renal Cell.

Enrollment
21st of 44
51 · median 46
Started
2012
with 1 other
Phase 1/2
6 of 44
none open now
Registered
35th of 44
by date

Among the 44 studies testing bevacizumab in Carcinoma, Renal Cell, this one is the 21st largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 1/2, and was the 35th registered.

Carcinoma, Renal Cell

2,043 studies on the registry are indexed under Carcinoma, Renal Cell; 395 are open to participants now.

Browse Carcinoma, Renal Cell studies →

Open to participants now

1 of the 44 studies testing bevacizumab in Carcinoma, Renal Cell is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About bevacizumab

Bevacizumab: first FDA approval 2004 (AVASTIN), first EMA approval 2005. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 308 Carcinoma, Renal Cell studies recruiting now, 255 (83%) set no upper age limit and 18 (6%) stop at 75 or younger; 21 take children under 18; 20 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing bevacizumab in Carcinoma, Renal Cell, or all of them as a file.
02

Study summary

This phase I/II trial studies the side effects and best dose of pazopanib hydrochloride and bevacizumab and to see how well they work in treating patients with previously untreated kidney cancer that has spread to other places in the body (metastatic). Pazopanib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Pazopanib hydrochloride may also stop the growth of tumor cells by blocking blood flow to the tumor. Monoclonal antibodies, such as bevacizumab, can prevent tumor growth by blocking the ability of tumor cells to grow and spread. Giving pazopanib hydrochloride together with bevacizumab may kill more tumor cells.

Read the detailed description

PRIMARY OBJECTIVES:

  • I. To determine the safe phase II dose of this novel regimen. (Phase I)
  • II. To determine the median progression free survival (PFS) from this novel regimen. (Phase II)

SECONDARY OBJECTIVES:

  • To evaluate the safety and toxicity of the proposed regimen. (Phase I)
  • To evaluate the response rate. (Phase I)
  • To evaluate the pharmacokinetics of pazopanib (pazopanib hydrochloride). (Phase I)

    • To evaluate the vascular endothelial growth factor (VEGF) levels and myeloid derived suppressor cell (MDSC) levels at various time points and correlate with response. (Phase I)
    • To evaluate the safety and toxicity of this new regimen. (Phase II)
    • To evaluate the VEGF levels, interleukin (IL)-8 levels and MDSC levels at various time points and correlate with outcome. (Phase II)
    • To evaluate the PFS rate at 12 months. (Phase II)
  • To evaluate overall survival. (Phase II)

OUTLINE: This is a phase I, dose-escalation study followed by a phase II study.

Patients receive pazopanib hydrochloride orally (PO) on days 1-28, and bevacizumab intravenously (IV) over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed up at 30 days and Phase II patients are followed up by telephone every 12 months

03

Conditions studied

  • Clear Cell Renal Cell Carcinoma
  • Stage IV Renal Cell Cancer
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • /pathology-proven clear cell renal cell carcinoma (CCRCC) with
  • Have an (ECOG) performance status =\< 1
  • >= 10 gm/dL
  • (ANC) >= 1.5 x 10\^9/L
  • >= 100 x 10\^9/L
  • Total =\< (ULN)
  • (ALT) and aspartate aminotransferase (AST) =\< ULN
  • International normalization ratio () and activated partial thromboplastin time (aPTT) \< 1.2 x ULN
  • Serum creatinine \< 1.5 mg/dL or if serum creatinine > 1.5 mg/dL then calculate (CrCL) > 30 mL/min
  • Urine protein to creatinine ratio =\< 1 (if urine protein creatinine ratio is > 1, then a 24-hour urine total protein must be assessed; subjects will be ineligible if the 24-hour urine protein is found to be > 1 gm)
  • Normal cardiac (> 50%) by multi gated acquisition scan (MUGA) or echocardiogram
  • Have per (RECIST) 1.1 criteria present
  • Ability to swallow and retain oral medication
  • Subjects of must agree to use adequate methods (e.g., hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation; should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately
  • Subject or legal representative must understand the nature of this study and sign an Independent Ethics Committee/Institutional Review Board approved written form prior to receiving any study related procedure

Exclusion criteria

Exclusion Criteria:

  • Subjects with known should be excluded from this clinical trial
  • Prior VEGF targeted therapies for renal cell carcinoma (RCC) including or neoadjuvant treatments; in phase 1 only, one prior therapy with high dose IL-2 or anti-programmed cell death (PD)-1 compound alone or in combination with cytotoxic T-lymphocyte-associated protein 4 () targeting drug is allowed on the trial
  • Subjects diagnosed with another cancer in the past 3 years; excluding basal cell carcinoma or squamous cell carcinoma, of skin which were completely cured by resection
  • Concurrent use of another anti-cancer drug including an anti-cancer agent
  • Major surgery within 28 days prior to treatment or major surgery planned during the next 6 months
  • Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic or psychiatric illness/social situations that would limit compliance with study requirements
  • History of any of the following cardio-vascular condition:

    • Myocardial infarction (MI)
    • Unstable angina
    • Coronary artery bypass grafting (CABG)-unless patient had a negative stress test within 6 months of screening
    • Coronary angioplasty or stenting
    • Symptomatic peripheral arterial disease (PAD)
    • History of symptomatic chronic congestive heart failure (CHF)
    • History of cerebrovascular accidents including (TIA)
    • interval (QTc) > 480 msec
    • Uncontrolled hypertension (systolic blood pressure [BP] > 150 mm Hg or diastolic BP of > 90 mm Hg); if the screening BP is elevated, adjustments in anti-hypertensives are permitted and a re-screening will be permitted for BP assessment with three consecutive values obtained 2 minutes apart; the 3 values have to be below 150/90 mm Hg for eligibility and can only be obtained after 2 days of the last change in anti-hypertensive medication; use of clonidine is not permissible for adjusting the BP during this period
  • History of deep vein thrombosis (DVT) or pulmonary embolism (PE) in the past 6 months
  • Subjects should not have packed red blood cells (PRBC) or transfusion within 14 days of the screening
  • Evidence of active bleeding or bleeding disorder
  • Subjects currently on anti-coagulation therapy are not eligible
  • Unable to discontinue the use of prohibited medications
  • Pregnant or nursing female subjects
  • Unwilling or unable to follow protocol requirements
  • Any condition which in the investigator's opinion deems the subject an unsuitable candidate to receive study drug
  • Received an investigational agent within 30 days prior to enrollment
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
51 participants (actual)

Study arms

  • Experimental
    Treatment (pazopanib hydrochloride and bevacizumab)

    Patients receive pazopanib hydrochloride PO on days 1-28 and bevacizumab IV over 30-90 minutes on days 36 and 50. Courses repeat every 70 days in the absence of disease progression or unacceptable toxicity.

    Biological: Bevacizumab · Other: Laboratory Biomarker Analysis · Drug: Pazopanib Hydrochloride · Other: Pharmacological Study

Interventions

  • BiologicalBevacizumab

    Given IV

    Also known as: Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF rhuMAb, Avastin, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF

  • OtherLaboratory Biomarker Analysis

    Correlative studies

  • DrugPazopanibStudies of PazopanibPazopanib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Given PO

    Also known as: GW786034B, Votrient

  • OtherPharmacological Study

    Correlative studies

06

What researchers measure

Primary outcomes

  1. Median PFS (Phase II)

    Distributions of continuous variables will be summarized with commonly used statistics (mean, standard deviation, median, etc.), with sub-group associations tested using the Wilcoxon Rank Sum test.

    Time frame: Up to 30 days post-treatment

  2. Optimal phase II dose, defined as the largest dose level at which less than 2 out of the 6 patients experienced dose-limiting toxicity, graded according to Common Terminology Criteria for Adverse Events version 4.0 (Phase I)

    The frequency of toxicities will be tabulated for the dose estimated to be the maximum-tolerated dose.

    Time frame: Up to 140 days

Secondary outcomes

  1. Incidence of grade 3 or higher toxicities, graded according to CTCAE version 4.0

    Categorical variables will be summarized in contingency tables, with associations of interest assessed using Fisher's exact test. The frequency of toxicities will be tabulated by grade across all dose levels and courses.

    Time frame: Up to 30 days post-treatment

  2. Overall survival (Phase II)

    Will be obtained using Kaplan-Meier and Proportional Hazards methods.

    Time frame: From the date of study enrollment to the date of death from any cause, assessed up to 30 days post-treatment

  3. PFS rate at 12 months (Phase II)

    Distributions of continuous variables will be summarized with commonly used statistics (mean, standard deviation, median, etc.), with sub-group associations tested using the Wilcoxon Rank Sum test.

    Time frame: At 12 months

  4. Response rate according to RECIST 1.1 (Phase I)

    Time frame: Up to 30 days post-treatment

Other outcomes

  1. IL-8 levels

    Distributions of continuous variables will be summarized with commonly used statistics (mean, standard deviation, median, etc.), with sub-group associations tested using the Wilcoxon Rank Sum test.

    Time frame: Up to 30 days post-treatment

  2. MDSC levels

    Distributions of continuous variables will be summarized with commonly used statistics (mean, standard deviation, median, etc.), with sub-group associations tested using the Wilcoxon Rank Sum test.

    Time frame: Up to 30 days post-treatment

  3. Pazopanib exposure as measured by pharmacokinetics parameters

    Time frame: Course 1 on day 1 at pre-dose, 2 hours, and 4 hours post-dose; day 15 at pre-dose and 2 hours post-dose; and day 29

  4. VEGF levels

    Distributions of continuous variables will be summarized with commonly used statistics (mean, standard deviation, median, etc.), with sub-group associations tested using the Wilcoxon Rank Sum test.

    Time frame: Up to 30 days post-treatment

07

Study locations

5 sites
08

References and documents

Publications

  • George S, Vaishampayan U, Hutson A, Groman A, Pili R, Green K, Herbst L, Kallicharan-Smith R, DiRaddo AM, Farrell E, Gopalakrishnan D, Heath E, Wulff E, Kilari D, Appleman L, Parikh R. Pazopanib alternating with bevacizumab in patients with metastatic clear-cell renal cell carcinoma naive to treatment: a multicentre, single-arm, phase 1/2 trial. Lancet Oncol. 2026 Oct 27:S1470-2045(26)00394-3. doi: 10.1016/S1470-2045(26)00394-3. Online ahead of print. PubMed 42945979 ↗
09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2012 (actual). Primary completion is estimated for Feb 2027, 170 months after the start.

Of 41 non-industry phase 1/2 interventional studies under Carcinoma, Renal Cell, half reached primary completion within 64 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 132. This study's planned 170 months is above that.

Counting every sponsor, half of 112 studies reached it within 64 months; a quarter within 45 and three quarters within 87.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 5, 2026: primary completion Aug 2026 → Feb 2027 and completion Aug 2026 → Feb 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Aug 24, 2012
First posted
Sep 13, 2012
StartActual
Nov 21, 2012
Primary completionEst.
Feb 20, 2027was Aug 2026
CompletionEst.
Feb 20, 2027was Aug 2026
Last update
Nov 5, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Aug 20, 2026→Feb 20, 2027
Nov 5, 2026
Study completion
Aug 20, 2026→Feb 20, 2027
Nov 5, 2026
Publications
1 publication citing this study linked from PubMed, e.g. PubMed 42945979 ↗
Nov 5, 2026
Show all 1 update
  1. Nov 5, 2026
    Publications 1 publication citing this study linked from PubMed, e.g. PubMed 42945979 ↗
    Primary completion Aug 20, 2026→Feb 20, 2027
    Study completion Aug 20, 2026→Feb 20, 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT01684397
Collaborators
GlaxoSmithKline
Responsible party
Sponsor
First posted
Sep 13, 2012
Start date
Nov 21, 2012
Primary completion
Feb 20, 2027 (estimated)
Completion
Feb 20, 2027 (estimated)
Last update
Nov 5, 2026

Study contacts

Saby George
principal investigator · Roswell Park Cancer Institute

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Bevacizumab · Pazopanib

Start the discussion